COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 12 FDA records to the applicant name Alcon Research, Ltd.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 10 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 26, 1991 to Oct 1, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MFK appears in 7 of the 12 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P040020, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 6201 S. Fwy., R3-48, Fort Worth, TX, 76134. Recorded on P890047/S072, decision dated Oct 1, 2026.
Device categories in this collection
Aid, Surgical, Viscoelastic; Lens, Multifocal Intraocular.
Changes described in PMA records
FDA recorded decision OK30 on 2026-10-01 for supplement S072 to PMA P890047, submitted by Alcon Research, Ltd. The supplement is a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, within the ophthalmic viscosurgical device category (product code LZP, specialty Ophthalmic). The identifier places S072 as a supplement to the existing P890047 PMA rather than a separate original approval.
The reported change is to the Endotoxin testing program for the subject ophthalmic viscosurgical devices (OVDs), including test article preparation and individual component testing. The record does not specify which endotoxin method, limits, sampling plan, components, or supplier site changed, nor does it state an outcome beyond the OK30 decision label. The stated purpose is a testing-program change; the entry gives no independent evidence of safety or clinical performance, and it creates no new indication or approval of the whole device system.
FDA approval-order wording
a change in the Endotoxin testing program for the subject ophthalmic viscosurgical devices (OVDs), including test article preparation and individual component testing
Oct 1, 2026 · 30-Day NoticeFDA’s recorded scope: An alternate manufacturing site at Alcon Fort Worth Manufacturing located at 6201 South Freeway, Fort Worth, Texas to perform the semiautomatic assembly of filled OVD (PROVISC, VISCOAT, and DUOVISC) syringes and components into blister packs, and packaging.
Aug 4, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: A new model of spin rinse dryer for the cleaning process for AcrySof ReSTOR, Clareon, Clareon Toric, and AcrySof Posterior Chamber IOLs
Jul 6, 2026 · 30-Day NoticeFDA’s recorded scope: a change to the image quality and IOL power measurement equipment for Clareon and AcrySof multifocal IOLs
Jul 2, 2026 · 30-Day NoticeFDA’s recorded scope: approval of ECH residual test method change at Alcon Research, LLC, WV USA
Jul 2, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.